242 related articles for article (PubMed ID: 33222197)
1. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N; Elli EM; Abruzzese E; Palumbo GA; Benevolo G; Tiribelli M; Bonifacio M; Tieghi A; Caocci G; D'Adda M; Bergamaschi M; Binotto G; Heidel FH; Cavazzini F; Crugnola M; Pugliese N; Bosi C; Isidori A; Bartoletti D; Auteri G; Latagliata R; Gandolfi L; Martino B; Scaffidi L; Cattaneo D; D'Amore F; Trawinska MM; Stella R; Markovic U; Catani L; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Vianelli N; Breccia M; Russo D; Cavo M; Iurlo A; Palandri F
Br J Haematol; 2021 Apr; 193(2):356-368. PubMed ID: 33222197
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Sekhri R; Sadjadian P; Becker T; Kolatzki V; Huenerbein K; Meixner R; Marchi H; Wallmann R; Fuchs C; Griesshammer M; Wille K
Ann Hematol; 2021 Nov; 100(11):2707-2716. PubMed ID: 34462786
[TBL] [Abstract][Full Text] [Related]
3. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
4. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I
Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851
[TBL] [Abstract][Full Text] [Related]
5. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M; Giorgino T; Mora B; Iurlo A; Elli E; Finazzi MC; Caramella M; Rumi E; Carraro MC; Polverelli N; D'Adda M; Malato S; Rossi M; Molteni A; Vismara A; Sissa C; Spina F; Anghilieri M; Cattaneo D; Renso R; Bellini M; Pioltelli ML; Cavalloni C; Barraco D; Accetta R; Bertù L; Della Porta MG; Passamonti F
Blood Adv; 2019 Nov; 3(21):3196-3200. PubMed ID: 31698448
[TBL] [Abstract][Full Text] [Related]
6. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
Lin JQ; Li SQ; Li S; Kiamanesh EF; Aasi SZ; Kwong BY; Su Chang AL
J Am Acad Dermatol; 2022 Feb; 86(2):339-344. PubMed ID: 34648874
[TBL] [Abstract][Full Text] [Related]
7. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
8. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
9. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis.
Baek DW; Cho HJ; Lee JM; Kim J; Moon JH; Sohn SK
Expert Rev Hematol; 2022 Jul; 15(7):573-581. PubMed ID: 35679520
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
[TBL] [Abstract][Full Text] [Related]
11. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
Thomas JW; Jamy O; Shah MV; Vachhani P; Go RS; Goyal G
Leuk Res; 2022 Jan; 112():106770. PubMed ID: 34920340
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
Polverelli N; Breccia M; Benevolo G; Martino B; Tieghi A; Latagliata R; Sabattini E; Riminucci M; Godio L; Catani L; Nicolosi M; Perricone M; Sollazzo D; Colafigli G; Campana A; Merli F; Vitolo U; Alimena G; Martinelli G; Lewis RE; Vianelli N; Cavo M; Palandri F
Am J Hematol; 2017 Jan; 92(1):37-41. PubMed ID: 27701770
[TBL] [Abstract][Full Text] [Related]
15. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.
Kirito K; Okamoto S; Ohishi K; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Oritani K; Akashi K; Okada H; Amagasaki T; Suzuki K; Yonezu T; Komatsu N
Int J Hematol; 2018 Jan; 107(1):92-97. PubMed ID: 28986762
[TBL] [Abstract][Full Text] [Related]
17. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M; Mora B; Ball S; Iurlo A; Elli EM; Finazzi MC; Polverelli N; Rumi E; Caramella M; Carraro MC; D'Adda M; Molteni A; Sissa C; Lunghi F; Vismara A; Ubezio M; Guidetti A; Caberlon S; Anghilieri M; Komrokji R; Cattaneo D; Della Porta MG; Giorgino T; Bertù L; Brociner M; Kuykendall A; Passamonti F
Blood Adv; 2022 Mar; 6(6):1855-1864. PubMed ID: 35130339
[TBL] [Abstract][Full Text] [Related]
18. Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib.
Blechman AB; Cabell CE; Weinberger CH; Duckworth A; Leitenberger JJ; Zwald FO; Russell MA
J Drugs Dermatol; 2017 May; 16(5):508-511. PubMed ID: 28628689
[TBL] [Abstract][Full Text] [Related]
19. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Palandri F; Palumbo GA; Benevolo G; Iurlo A; Elli EM; Abruzzese E; Polverelli N; Tiribelli M; Auteri G; Tieghi A; Caocci G; Binotto G; Cavazzini F; Branzanti F; Beggiato E; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Scaffidi L; Venturi M; Duminuco A; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Trawinska MM; Vianelli N; Cavo M; Bonifacio M; Breccia M
Cancer; 2024 Apr; 130(8):1270-1280. PubMed ID: 38153814
[TBL] [Abstract][Full Text] [Related]
20. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Mora B; Rumi E; Guglielmelli P; Barraco D; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Pietra D; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Giorgino T; Passamonti F
Cancer Med; 2019 Aug; 8(9):4089-4092. PubMed ID: 31173472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
